|
rs117829974
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study.
|
29923122 |
2018 |
|
rs2501846
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study.
|
29923122 |
2018 |
|
rs11719165
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We identified four loci possibly associated with gemcitabine-induced leukopenia/neutropenia [rs11141915 in DAPK1 on chromosome 9q21, combined P=1.27×10, odds ratio (OR)=4.10; rs1901440 on chromosome 2q12, combined P=3.11×10, OR=34.00; rs12046844 in PDE4B on chromosome 1p31, combined P=4.56×10, OR=4.13; rs11719165 on chromosome 3q29, combined P=5.98×10, OR=2.60].
|
22293537 |
2012 |
|
rs12046844
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We identified four loci possibly associated with gemcitabine-induced leukopenia/neutropenia [rs11141915 in DAPK1 on chromosome 9q21, combined P=1.27×10, odds ratio (OR)=4.10; rs1901440 on chromosome 2q12, combined P=3.11×10, OR=34.00; rs12046844 in PDE4B on chromosome 1p31, combined P=4.56×10, OR=4.13; rs11719165 on chromosome 3q29, combined P=5.98×10, OR=2.60].
|
22293537 |
2012 |
|
rs16957920
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The GWAS identified two loci associated with thiopurine-induced leukopenia (rs16957920, <i>FTO</i> intron; rs2834826, <i>RUNX1</i> intergenic).
|
27558924 |
2017 |
|
rs1901440
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We identified four loci possibly associated with gemcitabine-induced leukopenia/neutropenia [rs11141915 in DAPK1 on chromosome 9q21, combined P=1.27×10, odds ratio (OR)=4.10; rs1901440 on chromosome 2q12, combined P=3.11×10, OR=34.00; rs12046844 in PDE4B on chromosome 1p31, combined P=4.56×10, OR=4.13; rs11719165 on chromosome 3q29, combined P=5.98×10, OR=2.60].
|
22293537 |
2012 |
|
rs6478317
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Four SNPs in the TLR4 gene (rs10759931, rs11536889, rs1927911 and rs6478317) were associated with an increased risk of developing chemotherapy-induced neutropenia, each sustaining correction for multiple testing.
|
21403649 |
2011 |
|
rs7091672
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In contrast, 4 of the positively selected SNPs (rs1409314, rs4752219, rs4752220 and rs7091672) were significantly correlated with the toxicities tested (neutropenia, anemia, thrombocytopenia, emesis and hepatotoxicity).
|
25732572 |
2015 |
|
rs1045642
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Serum LDH may be a promising predictor of prognosis, and the ABCB1 C3435T polymorphism may be a genetic predictor of the severity of leukocytopenia in patients with CRPC treated with DEC.
|
21706123 |
2012 |
|
rs1045642
|
|
|
0.100 |
GeneticVariation |
BEFREE |
PG analysis showed that ABCB1 (C3435T)T/T (membrane transport) was associated with IP-related diarrhea; UGT1A1 (G-3156A)A/A (drug metabolism) was associated with IP-related neutropenia.
|
19349543 |
2009 |
|
rs1045642
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Statistical associations were observed, suggesting a lower risk of neutropenia (p = 0.013) and hand-foot syndrome (HFS; p = 0.027) for the carriers of T variation for rs1128503 in capecitabine-treated patients, carriers of T variation for rs1045642 treated with capecitabine had a lower risk of HFS (p = 0.033), while those treated with 5-FU had a higher risk of diarrhea (p = 0.035), and carriers of T variation for rs2032592 treated with capecitabine were at less risk of developing HFS (p = 0.033).
|
21142915 |
2010 |
|
rs1045642
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In addition, a statistically significant association was found among neutropenia (absolute neutrophil count<500) and variant allele carriers of ABCB1 rs1045642 (OR=5.174; 95% CI: 1.674; 15.989) and ABCB1 rs1128503 (OR=3.364; 95% CI: 1.257; 9.004), respectively.
|
25007187 |
2014 |
|
rs1045642
|
|
|
0.100 |
GeneticVariation |
BEFREE |
On evaluating higher order gene-gene interaction models by MDR analysis, CYP3A5*3; ABCB11236C>T and ABCB1 2677G>T/A; ABCB1 3435C>T and CYP1B1*3 showed significant association with treatment response, grade 2-4 anemia and dose delay/reduction due to neutropenia (P=0.024, P=0.004, P=0.026), respectively.
|
24704000 |
2014 |
|
rs1045642
|
|
|
0.100 |
GeneticVariation |
BEFREE |
C3435T polymorphisms of ABCB1 might be able to predict severe amrubicin-induced neutropenia.
|
24982363 |
2014 |
|
rs1045642
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Associations were found between toxicities and gene variants (P<0.05), including neutropenia with ABCB1 (rs1045642) and SLC0B3 (rs4149117 and rs7311358); and diarrhoea with CYP2C9 (rs1057910), CYP2C19 (rs3758581), UGT1A6 (rs4124874) and SLC22A1 (rs72552763).
|
28817838 |
2017 |
|
rs1045642
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Individuals who were CC homozygotes at MDR1 rs1045642 had lower risk of having methotrexate plasma concentrations >1 μM and leukopenia grade I (odds ratio [OR] = 0.30; 95% CI = 0.13-0.72 and OR = 0.32; 95% CI = 0.14-0.72, respectively).
|
27533339 |
2016 |
|
rs1045642
|
|
|
0.100 |
GeneticVariation |
BEFREE |
With regard to ABCB1 3435 C>T, ABCB1 3435 T/T had significantly higher risks of neutropenia (P = 0.015).
|
22271208 |
2012 |
|
rs1045642
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We found that patients carrying the CYP3A5*1/*3 genotype demonstrated more side effects of fever, pleural effusion, and febrile neutropenia than those with the CYP3A5*3/*3 genotype (p = 0.075, 0.077, and 0.030, respectively); moreover, patients with the ABCB1 2677G/G genotype also showed more side effects of fever and febrile neutropenia than those with other genotypes (p = 0.024 and 0.027), In regard to ABCB1 3435C>T, patients with ABCB1 3435C/C tended to suffer leucopenia (p = 0.057).
|
19332043 |
2009 |
|
rs1045642
|
|
|
0.100 |
GeneticVariation |
BEFREE |
CYP2C8*3 and the ABCB1 SNPs C1236T, G2677T/A, and C3435T were not statistically significantly correlated to overall survival, sensoric neuropathy, and neutropenia in 119 patients treated for ovarian cancer with paclitaxel/carboplatin.
|
21327421 |
2011 |
|
rs2032582
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Delayed time to neutropenia recovery was observed with ABCB1 rs2032582 variant (p = .047).
|
27701910 |
2017 |
|
rs2032582
|
|
|
0.050 |
GeneticVariation |
BEFREE |
On evaluating higher order gene-gene interaction models by MDR analysis, CYP3A5*3; ABCB11236C>T and ABCB1 2677G>T/A; ABCB1 3435C>T and CYP1B1*3 showed significant association with treatment response, grade 2-4 anemia and dose delay/reduction due to neutropenia (P=0.024, P=0.004, P=0.026), respectively.
|
24704000 |
2014 |
|
rs2032582
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The multivariate logistic regression analysis revealed that the ABCB1 2677G>T/A polymorphism was a strong predictor of grade 3 or greater neutropenia (odds ratio: 3.76; 95% confidence interval: 1.44-9.81; p = 0.007).
|
25989890 |
2015 |
|
rs2032582
|
|
|
0.050 |
GeneticVariation |
BEFREE |
In toxicity, the 2677G/T or A was associated with grade 4 neutropenia.
|
17534875 |
2007 |
|
rs2032582
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Meta-analysis showed an decreased risk of irinotecan-induced neutropenia in patients expressing ABCB1 2677G>T/G (odds ratio [OR]: 0.24; 95% CI: 0.1-0.59; p = 0.002) but increased risk for ABCC2 3972T>T (OR: 1.67; 95% CI: 1.01-2.74; p = 0.04).
|
27269636 |
2016 |
|
rs1128503
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Statistical associations were observed, suggesting a lower risk of neutropenia (p = 0.013) and hand-foot syndrome (HFS; p = 0.027) for the carriers of T variation for rs1128503 in capecitabine-treated patients, carriers of T variation for rs1045642 treated with capecitabine had a lower risk of HFS (p = 0.033), while those treated with 5-FU had a higher risk of diarrhea (p = 0.035), and carriers of T variation for rs2032592 treated with capecitabine were at less risk of developing HFS (p = 0.033).
|
21142915 |
2010 |